Cellebrite DI Ltd. $CLBT Shares Purchased by PEAK6 LLC

Key Points

• PEAK6 LLC increased its holdings in Cellebrite DI Ltd. by 72.8%, owning 55,465 shares worth approximately $1.08 million following an additional acquisition of 23,366 shares.
• Cellebrite DI reported a profit of $0.12 EPS for the last quarter, surpassing analysts' expectations and representing an 18.4% revenue growth from the previous year.
• Several analysts upgraded Cellebrite DI's stock rating, with a consensus now rated as a "Buy" and an average target price of $22.40.

PEAK6 LLC increased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 72.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,465 shares of the company's stock after purchasing an additional 23,366 shares during the period. PEAK6 LLC's holdings in Cellebrite DI were worth $1,078,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bosun Asset Management LLC increased its holdings in Cellebrite DI by 1.4% in the fourth quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock valued at $954,000 after buying an additional 584 shares in the last quarter. OneDigital Investment Advisors LLC increased its holdings in Cellebrite DI by 2.5% in the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock valued at $556,000 after buying an additional 688 shares in the last quarter. Assetmark Inc. purchased a new position in Cellebrite DI in the first quarter valued at $33,000. HighTower Advisors LLC increased its holdings in Cellebrite DI by 16.3% in the first quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock valued at $281,000 after buying an additional 2,029 shares in the last quarter. Finally, Catalyst Capital Advisors LLC purchased a new position in Cellebrite DI in the first quarter valued at $51,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on CLBT shares. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Lake Street Capital cut their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $22.40.

Cellebrite DI Stock Performance

Shares of CLBT stock traded down $0.14 on Thursday, reaching $16.37. 4,336,036 shares of the company were exchanged, compared to its average volume of 2,422,649. The company has a market cap of $3.92 billion, a price-to-earnings ratio of -21.54, a P/E/G ratio of 3.00 and a beta of 1.28. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The business has a 50-day moving average price of $15.01 and a 200 day moving average price of $17.06.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The firm had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. Cellebrite DI's quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.